English
简体中文
Total: £ 56.28
Published Date: 2025-12-04 | Pages: 91 | Tables: 89 | Pharma & Healthcare
The global market for Growth Hormone Inhibiting Hormone Drug was valued at US$ 5315 million in the year 2024 and is projected to reach a revised size of US$ 12034 million by 2031, growing at a CAGR of 12.3% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Growth Hormone Inhibiting Hormone Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Growth Hormone Inhibiting Hormone Drug refers to a class of therapeutics that mimic or potentiate the physiological actions of somatostatin, thereby suppressing the secretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), and multiple endocrine gland activities. This category includes native somatostatin, synthetic somatostatin analogs (such as octreotide, lanreotide, pasireotide), next-generation long-acting delivery formulations, oral small-molecule agonists, and receptor-selective agents. By activating specific SSTR receptor subtypes, these drugs regulate hormone release and inhibit tumor cell proliferation, with broad clinical applications in acromegaly, neuroendocrine tumors, gastrointestinal hormone disorders, and thyroid conditions.In 2024, global Growth Hormone Inhibiting Hormone Drug production reached approximately 265.75 m units, with an average global market price of around US$ 20 perunit.The average gross profit margin of this product is 65%.
The market for Growth Hormone Inhibiting Hormone Drugs is being propelled by rising demand for endocrine disease management, the expanding adoption of standardized neuroendocrine tumor treatment, and continuous optimization of regulatory pathways for innovative drugs. Annual reports from leading companies highlight that product upgrades—particularly long-acting formulations, multi-receptor agonists with stronger targeting specificity, and more convenient administration routes—are accelerating the shift toward high-value markets and broader indications. Brokerage research further underscores the enhancement of biopharmaceutical manufacturing capacity and global investment in continuous production and bioprocess optimization, strengthening commercialization potential.
Despite strong momentum, the industry faces challenges related to manufacturing complexity, stringent purity and stability requirements, and increasingly tightened supply-chain oversight. Several companies report that large-scale production of complex peptide drugs remains technically demanding. In addition, competition from generics, pressure from reimbursement policies, and uncertainty in pricing reforms may influence profitability. Regulators are raising expectations for quality consistency and full-process compliance, prompting companies to invest more in quality systems and sustainable supply reliability.
Demand is rapidly increasing in three areas: earlier and standardized diagnosis in endocrine diseases; wider clinical pathway inclusion of neuroendocrine tumors, enabling broader first- and second-line use of innovative therapies; and hospital preference for long-acting, personalized, and more convenient formulations. Annual reports also emphasize the accelerating shift toward long-cycle, home-compatible treatment solutions. Real-world evidence is strengthening physician confidence and facilitating clinical adoption.
Upstream materials include complex peptide APIs, synthesis resins and amino acids, conjugation and modification reagents, and materials for long-acting delivery systems. Raw-material suppliers emphasize in annual reports that stringent quality control and environmental stability are essential for consistent manufacturing. With governments prioritizing biopharmaceutical supply-chain resilience, localization and diversification of raw-material sources are becoming critical. Long-acting formulation materials—such as polymers, microspheres, and lipid-based carriers—are increasingly important in partner selection and supply strategy.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Growth Hormone Inhibiting Hormone Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Growth Hormone Inhibiting Hormone Drug.
The Growth Hormone Inhibiting Hormone Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Growth Hormone Inhibiting Hormone Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, by Route of Administration and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Growth Hormone Inhibiting Hormone Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Route of Administration and by regions.
By Company
Novartis AG
Merck KGaA
Pfizer
Novo Nordisk
Biopartners GmbH
Ipsen
GeneScience Pharmaceuticals
Teva
Viatris
Cipla
Intas
Shuangcheng Pharma
Hanyu Pharmaceutical
Tiantaishan Pharmaceutical
Yangtze River Pharmaceutical
Segment by Type
Hypothalamic Peptide Hormone
Gastrointestinal Peptide Hormones
Segment by Route of Administration
Long-acting Injectable
Short-acting Injectable
Other
Segment by Therapeutic Indications
Acromegaly
Neuroendocrine Tumors (NETs)
Pituitary Disorders
Other
Segment by Application
Hospital
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Growth Hormone Inhibiting Hormone Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Growth Hormone Inhibiting Hormone Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Growth Hormone Inhibiting Hormone Drug Market Overview
1.1 Product Definition
1.2 Growth Hormone Inhibiting Hormone Drug by Type
1.2.1 Global Growth Hormone Inhibiting Hormone Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Hypothalamic Peptide Hormone
1.2.3 Gastrointestinal Peptide Hormones
1.3 Growth Hormone Inhibiting Hormone Drug by Route of Administration
1.3.1 Global Growth Hormone Inhibiting Hormone Drug Market Value Comparison by Route of Administration: 2024 VS 2031
1.3.2 Long-acting Injectable
1.3.3 Short-acting Injectable
1.3.4 Other
1.4 Growth Hormone Inhibiting Hormone Drug by Therapeutic Indications
1.4.1 Global Growth Hormone Inhibiting Hormone Drug Market Value Comparison by Therapeutic Indications: 2024 VS 2031
1.4.2 Acromegaly
1.4.3 Neuroendocrine Tumors (NETs)
1.4.4 Pituitary Disorders
1.4.5 Other
1.5 Growth Hormone Inhibiting Hormone Drug by Application
1.5.1 Global Growth Hormone Inhibiting Hormone Drug Market Value by Application (2024 VS 2031)
1.5.2 Hospital
1.5.3 Retail Pharmacy
1.5.4 Other
1.6 Global Growth Hormone Inhibiting Hormone Drug Market Size Estimates and Forecasts
1.6.1 Global Growth Hormone Inhibiting Hormone Drug Revenue 2020-2031
1.6.2 Global Growth Hormone Inhibiting Hormone Drug Sales 2020-2031
1.6.3 Global Growth Hormone Inhibiting Hormone Drug Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Growth Hormone Inhibiting Hormone Drug Market Competition by Manufacturers
2.1 Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Growth Hormone Inhibiting Hormone Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Growth Hormone Inhibiting Hormone Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Product Type & Application
2.7 Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Date of Enter into This Industry
2.8 Global Growth Hormone Inhibiting Hormone Drug Market Competitive Situation and Trends
2.8.1 Global Growth Hormone Inhibiting Hormone Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Growth Hormone Inhibiting Hormone Drug Players Market Share by Revenue
2.8.3 Global Growth Hormone Inhibiting Hormone Drug Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Growth Hormone Inhibiting Hormone Drug Market Scenario by Region
3.1 Global Growth Hormone Inhibiting Hormone Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Growth Hormone Inhibiting Hormone Drug Sales by Region: 2020-2031
3.2.1 Global Growth Hormone Inhibiting Hormone Drug Sales by Region: 2020-2025
3.2.2 Global Growth Hormone Inhibiting Hormone Drug Sales by Region: 2026-2031
3.3 Global Growth Hormone Inhibiting Hormone Drug Revenue by Region: 2020-2031
3.3.1 Global Growth Hormone Inhibiting Hormone Drug Revenue by Region: 2020-2025
3.3.2 Global Growth Hormone Inhibiting Hormone Drug Revenue by Region: 2026-2031
3.4 North America Growth Hormone Inhibiting Hormone Drug Market Facts & Figures by Country
3.4.1 North America Growth Hormone Inhibiting Hormone Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2031)
3.4.3 North America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Growth Hormone Inhibiting Hormone Drug Market Facts & Figures by Country
3.5.1 Europe Growth Hormone Inhibiting Hormone Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2031)
3.5.3 Europe Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Growth Hormone Inhibiting Hormone Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Growth Hormone Inhibiting Hormone Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Growth Hormone Inhibiting Hormone Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Growth Hormone Inhibiting Hormone Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Growth Hormone Inhibiting Hormone Drug Market Facts & Figures by Country
3.7.1 Latin America Growth Hormone Inhibiting Hormone Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2031)
3.7.3 Latin America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Growth Hormone Inhibiting Hormone Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Growth Hormone Inhibiting Hormone Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Growth Hormone Inhibiting Hormone Drug Sales by Type (2020-2031)
4.1.1 Global Growth Hormone Inhibiting Hormone Drug Sales by Type (2020-2025)
4.1.2 Global Growth Hormone Inhibiting Hormone Drug Sales by Type (2026-2031)
4.1.3 Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Type (2020-2031)
4.2 Global Growth Hormone Inhibiting Hormone Drug Revenue by Type (2020-2031)
4.2.1 Global Growth Hormone Inhibiting Hormone Drug Revenue by Type (2020-2025)
4.2.2 Global Growth Hormone Inhibiting Hormone Drug Revenue by Type (2026-2031)
4.2.3 Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Type (2020-2031)
4.3 Global Growth Hormone Inhibiting Hormone Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Growth Hormone Inhibiting Hormone Drug Sales by Application (2020-2031)
5.1.1 Global Growth Hormone Inhibiting Hormone Drug Sales by Application (2020-2025)
5.1.2 Global Growth Hormone Inhibiting Hormone Drug Sales by Application (2026-2031)
5.1.3 Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Application (2020-2031)
5.2 Global Growth Hormone Inhibiting Hormone Drug Revenue by Application (2020-2031)
5.2.1 Global Growth Hormone Inhibiting Hormone Drug Revenue by Application (2020-2025)
5.2.2 Global Growth Hormone Inhibiting Hormone Drug Revenue by Application (2026-2031)
5.2.3 Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Application (2020-2031)
5.3 Global Growth Hormone Inhibiting Hormone Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Company Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Merck KGaA
6.2.1 Merck KGaA Company Information
6.2.2 Merck KGaA Description and Business Overview
6.2.3 Merck KGaA Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck KGaA Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.2.5 Merck KGaA Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Company Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novo Nordisk Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Biopartners GmbH
6.5.1 Biopartners GmbH Company Information
6.5.2 Biopartners GmbH Description and Business Overview
6.5.3 Biopartners GmbH Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Biopartners GmbH Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.5.5 Biopartners GmbH Recent Developments/Updates
6.6 Ipsen
6.6.1 Ipsen Company Information
6.6.2 Ipsen Description and Business Overview
6.6.3 Ipsen Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Ipsen Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.6.5 Ipsen Recent Developments/Updates
6.7 GeneScience Pharmaceuticals
6.7.1 GeneScience Pharmaceuticals Company Information
6.7.2 GeneScience Pharmaceuticals Description and Business Overview
6.7.3 GeneScience Pharmaceuticals Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 GeneScience Pharmaceuticals Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.7.5 GeneScience Pharmaceuticals Recent Developments/Updates
6.8 Teva
6.8.1 Teva Company Information
6.8.2 Teva Description and Business Overview
6.8.3 Teva Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Teva Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.8.5 Teva Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Company Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Viatris Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Cipla
6.10.1 Cipla Company Information
6.10.2 Cipla Description and Business Overview
6.10.3 Cipla Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Cipla Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.10.5 Cipla Recent Developments/Updates
6.11 Intas
6.11.1 Intas Company Information
6.11.2 Intas Description and Business Overview
6.11.3 Intas Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Intas Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.11.5 Intas Recent Developments/Updates
6.12 Shuangcheng Pharma
6.12.1 Shuangcheng Pharma Company Information
6.12.2 Shuangcheng Pharma Description and Business Overview
6.12.3 Shuangcheng Pharma Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Shuangcheng Pharma Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.12.5 Shuangcheng Pharma Recent Developments/Updates
6.13 Hanyu Pharmaceutical
6.13.1 Hanyu Pharmaceutical Company Information
6.13.2 Hanyu Pharmaceutical Description and Business Overview
6.13.3 Hanyu Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Hanyu Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.13.5 Hanyu Pharmaceutical Recent Developments/Updates
6.14 Tiantaishan Pharmaceutical
6.14.1 Tiantaishan Pharmaceutical Company Information
6.14.2 Tiantaishan Pharmaceutical Description and Business Overview
6.14.3 Tiantaishan Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Tiantaishan Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.14.5 Tiantaishan Pharmaceutical Recent Developments/Updates
6.15 Yangtze River Pharmaceutical
6.15.1 Yangtze River Pharmaceutical Company Information
6.15.2 Yangtze River Pharmaceutical Description and Business Overview
6.15.3 Yangtze River Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Yangtze River Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product Portfolio
6.15.5 Yangtze River Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Growth Hormone Inhibiting Hormone Drug Industry Chain Analysis
7.2 Growth Hormone Inhibiting Hormone Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Growth Hormone Inhibiting Hormone Drug Production Mode & Process Analysis
7.4 Growth Hormone Inhibiting Hormone Drug Sales and Marketing
7.4.1 Growth Hormone Inhibiting Hormone Drug Sales Channels
7.4.2 Growth Hormone Inhibiting Hormone Drug Distributors
7.5 Growth Hormone Inhibiting Hormone Drug Customer Analysis
8 Growth Hormone Inhibiting Hormone Drug Market Dynamics
8.1 Growth Hormone Inhibiting Hormone Drug Industry Trends
8.2 Growth Hormone Inhibiting Hormone Drug Market Drivers
8.3 Growth Hormone Inhibiting Hormone Drug Market Challenges
8.4 Growth Hormone Inhibiting Hormone Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Growth Hormone Inhibiting Hormone Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Growth Hormone Inhibiting Hormone Drug Market Value by Route of Administration, (US$ Million) & (2024 VS 2031)
Table 3. Global Growth Hormone Inhibiting Hormone Drug Market Value by Therapeutic Indications, (US$ Million) & (2024 VS 2031)
Table 4. Global Growth Hormone Inhibiting Hormone Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 5. Global Growth Hormone Inhibiting Hormone Drug Market Competitive Situation by Manufacturers in 2024
Table 6. Global Growth Hormone Inhibiting Hormone Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 7. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Growth Hormone Inhibiting Hormone Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 9. Global Growth Hormone Inhibiting Hormone Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Growth Hormone Inhibiting Hormone Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 11. Global Key Players of Growth Hormone Inhibiting Hormone Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Manufacturing Sites & Headquarters
Table 13. Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Product Type & Application
Table 14. Global Key Manufacturers of Growth Hormone Inhibiting Hormone Drug, Date of Enter into This Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Growth Hormone Inhibiting Hormone Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Growth Hormone Inhibiting Hormone Drug as of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Growth Hormone Inhibiting Hormone Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 19. Global Growth Hormone Inhibiting Hormone Drug Sales by Region (2020-2025) & (K Units)
Table 20. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Region (2020-2025)
Table 21. Global Growth Hormone Inhibiting Hormone Drug Sales by Region (2026-2031) & (K Units)
Table 22. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Region (2026-2031)
Table 23. Global Growth Hormone Inhibiting Hormone Drug Revenue by Region (2020-2025) & (US$ Million)
Table 24. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Region (2020-2025)
Table 25. Global Growth Hormone Inhibiting Hormone Drug Revenue by Region (2026-2031) & (US$ Million)
Table 26. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Region (2026-2031)
Table 27. North America Growth Hormone Inhibiting Hormone Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. North America Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2025) & (K Units)
Table 29. North America Growth Hormone Inhibiting Hormone Drug Sales by Country (2026-2031) & (K Units)
Table 30. North America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2025) & (US$ Million)
Table 31. North America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2026-2031) & (US$ Million)
Table 32. Europe Growth Hormone Inhibiting Hormone Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 33. Europe Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2025) & (K Units)
Table 34. Europe Growth Hormone Inhibiting Hormone Drug Sales by Country (2026-2031) & (K Units)
Table 35. Europe Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2025) & (US$ Million)
Table 36. Europe Growth Hormone Inhibiting Hormone Drug Revenue by Country (2026-2031) & (US$ Million)
Table 37. Asia Pacific Growth Hormone Inhibiting Hormone Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 38. Asia Pacific Growth Hormone Inhibiting Hormone Drug Sales by Region (2020-2025) & (K Units)
Table 39. Asia Pacific Growth Hormone Inhibiting Hormone Drug Sales by Region (2026-2031) & (K Units)
Table 40. Asia Pacific Growth Hormone Inhibiting Hormone Drug Revenue by Region (2020-2025) & (US$ Million)
Table 41. Asia Pacific Growth Hormone Inhibiting Hormone Drug Revenue by Region (2026-2031) & (US$ Million)
Table 42. Latin America Growth Hormone Inhibiting Hormone Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Latin America Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2025) & (K Units)
Table 44. Latin America Growth Hormone Inhibiting Hormone Drug Sales by Country (2026-2031) & (K Units)
Table 45. Latin America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2025) & (US$ Million)
Table 46. Latin America Growth Hormone Inhibiting Hormone Drug Revenue by Country (2026-2031) & (US$ Million)
Table 47. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 48. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Sales by Country (2020-2025) & (K Units)
Table 49. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Sales by Country (2026-2031) & (K Units)
Table 50. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Revenue by Country (2020-2025) & (US$ Million)
Table 51. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Revenue by Country (2026-2031) & (US$ Million)
Table 52. Global Growth Hormone Inhibiting Hormone Drug Sales (K Units) by Type (2020-2025)
Table 53. Global Growth Hormone Inhibiting Hormone Drug Sales (K Units) by Type (2026-2031)
Table 54. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Type (2020-2025)
Table 55. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Type (2026-2031)
Table 56. Global Growth Hormone Inhibiting Hormone Drug Revenue (US$ Million) by Type (2020-2025)
Table 57. Global Growth Hormone Inhibiting Hormone Drug Revenue (US$ Million) by Type (2026-2031)
Table 58. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Type (2020-2025)
Table 59. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Type (2026-2031)
Table 60. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Type (2020-2025)
Table 61. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Type (2026-2031)
Table 62. Global Growth Hormone Inhibiting Hormone Drug Sales (K Units) by Application (2020-2025)
Table 63. Global Growth Hormone Inhibiting Hormone Drug Sales (K Units) by Application (2026-2031)
Table 64. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Application (2020-2025)
Table 65. Global Growth Hormone Inhibiting Hormone Drug Sales Market Share by Application (2026-2031)
Table 66. Global Growth Hormone Inhibiting Hormone Drug Revenue (US$ Million) by Application (2020-2025)
Table 67. Global Growth Hormone Inhibiting Hormone Drug Revenue (US$ Million) by Application (2026-2031)
Table 68. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Application (2020-2025)
Table 69. Global Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Application (2026-2031)
Table 70. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Application (2020-2025)
Table 71. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Application (2026-2031)
Table 72. Novartis AG Company Information
Table 73. Novartis AG Description and Business Overview
Table 74. Novartis AG Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Novartis AG Growth Hormone Inhibiting Hormone Drug Product
Table 76. Novartis AG Recent Developments/Updates
Table 77. Merck KGaA Company Information
Table 78. Merck KGaA Description and Business Overview
Table 79. Merck KGaA Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Merck KGaA Growth Hormone Inhibiting Hormone Drug Product
Table 81. Merck KGaA Recent Developments/Updates
Table 82. Pfizer Company Information
Table 83. Pfizer Description and Business Overview
Table 84. Pfizer Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Pfizer Growth Hormone Inhibiting Hormone Drug Product
Table 86. Pfizer Recent Developments/Updates
Table 87. Novo Nordisk Company Information
Table 88. Novo Nordisk Description and Business Overview
Table 89. Novo Nordisk Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Novo Nordisk Growth Hormone Inhibiting Hormone Drug Product
Table 91. Novo Nordisk Recent Developments/Updates
Table 92. Biopartners GmbH Company Information
Table 93. Biopartners GmbH Description and Business Overview
Table 94. Biopartners GmbH Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Biopartners GmbH Growth Hormone Inhibiting Hormone Drug Product
Table 96. Biopartners GmbH Recent Developments/Updates
Table 97. Ipsen Company Information
Table 98. Ipsen Description and Business Overview
Table 99. Ipsen Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Ipsen Growth Hormone Inhibiting Hormone Drug Product
Table 101. Ipsen Recent Developments/Updates
Table 102. GeneScience Pharmaceuticals Company Information
Table 103. GeneScience Pharmaceuticals Description and Business Overview
Table 104. GeneScience Pharmaceuticals Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. GeneScience Pharmaceuticals Growth Hormone Inhibiting Hormone Drug Product
Table 106. GeneScience Pharmaceuticals Recent Developments/Updates
Table 107. Teva Company Information
Table 108. Teva Description and Business Overview
Table 109. Teva Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Teva Growth Hormone Inhibiting Hormone Drug Product
Table 111. Teva Recent Developments/Updates
Table 112. Viatris Company Information
Table 113. Viatris Description and Business Overview
Table 114. Viatris Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Viatris Growth Hormone Inhibiting Hormone Drug Product
Table 116. Viatris Recent Developments/Updates
Table 117. Cipla Company Information
Table 118. Cipla Description and Business Overview
Table 119. Cipla Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. Cipla Growth Hormone Inhibiting Hormone Drug Product
Table 121. Cipla Recent Developments/Updates
Table 122. Intas Company Information
Table 123. Intas Description and Business Overview
Table 124. Intas Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 125. Intas Growth Hormone Inhibiting Hormone Drug Product
Table 126. Intas Recent Developments/Updates
Table 127. Shuangcheng Pharma Company Information
Table 128. Shuangcheng Pharma Description and Business Overview
Table 129. Shuangcheng Pharma Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 130. Shuangcheng Pharma Growth Hormone Inhibiting Hormone Drug Product
Table 131. Shuangcheng Pharma Recent Developments/Updates
Table 132. Hanyu Pharmaceutical Company Information
Table 133. Hanyu Pharmaceutical Description and Business Overview
Table 134. Hanyu Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 135. Hanyu Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product
Table 136. Hanyu Pharmaceutical Recent Developments/Updates
Table 137. Tiantaishan Pharmaceutical Company Information
Table 138. Tiantaishan Pharmaceutical Description and Business Overview
Table 139. Tiantaishan Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 140. Tiantaishan Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product
Table 141. Tiantaishan Pharmaceutical Recent Developments/Updates
Table 142. Yangtze River Pharmaceutical Company Information
Table 143. Yangtze River Pharmaceutical Description and Business Overview
Table 144. Yangtze River Pharmaceutical Growth Hormone Inhibiting Hormone Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 145. Yangtze River Pharmaceutical Growth Hormone Inhibiting Hormone Drug Product
Table 146. Yangtze River Pharmaceutical Recent Developments/Updates
Table 147. Key Raw Materials Lists
Table 148. Raw Materials Key Suppliers Lists
Table 149. Growth Hormone Inhibiting Hormone Drug Distributors List
Table 150. Growth Hormone Inhibiting Hormone Drug Customers List
Table 151. Growth Hormone Inhibiting Hormone Drug Market Trends
Table 152. Growth Hormone Inhibiting Hormone Drug Market Drivers
Table 153. Growth Hormone Inhibiting Hormone Drug Market Challenges
Table 154. Growth Hormone Inhibiting Hormone Drug Market Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
Table 158. Authors List of This Report
List of Figures
Figure 1. Product Picture of Growth Hormone Inhibiting Hormone Drug
Figure 2. Global Growth Hormone Inhibiting Hormone Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Growth Hormone Inhibiting Hormone Drug Market Share by Type: 2024 & 2031
Figure 4. Hypothalamic Peptide Hormone Product Picture
Figure 5. Gastrointestinal Peptide Hormones Product Picture
Figure 6. Global Growth Hormone Inhibiting Hormone Drug Market Value by Route of Administration, (US$ Million) & (2020-2031)
Figure 7. Global Growth Hormone Inhibiting Hormone Drug Market Share by Route of Administration: 2024 VS 2031
Figure 8. Long-acting Injectable Product Picture
Figure 9. Short-acting Injectable Product Picture
Figure 10. Other Product Picture
Figure 11. Global Growth Hormone Inhibiting Hormone Drug Market Value by Therapeutic Indications, (US$ Million) & (2020-2031)
Figure 12. Global Growth Hormone Inhibiting Hormone Drug Market Share by Therapeutic Indications: 2024 VS 2031
Figure 13. Acromegaly Product Picture
Figure 14. Neuroendocrine Tumors (NETs) Product Picture
Figure 15. Pituitary Disorders Product Picture
Figure 16. Other Product Picture
Figure 17. Global Growth Hormone Inhibiting Hormone Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 18. Global Growth Hormone Inhibiting Hormone Drug Market Share by Application: 2024 & 2031
Figure 19. Hospital
Figure 20. Retail Pharmacy
Figure 21. Other
Figure 22. Global Growth Hormone Inhibiting Hormone Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 23. Global Growth Hormone Inhibiting Hormone Drug Market Size (2020-2031) & (US$ Million)
Figure 24. Global Growth Hormone Inhibiting Hormone Drug Sales (2020-2031) & (K Units)
Figure 25. Global Growth Hormone Inhibiting Hormone Drug Average Price (US$/Unit) & (2020-2031)
Figure 26. Growth Hormone Inhibiting Hormone Drug Report Years Considered
Figure 27. Growth Hormone Inhibiting Hormone Drug Sales Share by Manufacturers in 2024
Figure 28. Global Growth Hormone Inhibiting Hormone Drug Revenue Share by Manufacturers in 2024
Figure 29. Global 5 and 10 Largest Growth Hormone Inhibiting Hormone Drug Players: Market Share by Revenue in Growth Hormone Inhibiting Hormone Drug in 2024
Figure 30. Growth Hormone Inhibiting Hormone Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 31. Global Growth Hormone Inhibiting Hormone Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 32. North America Growth Hormone Inhibiting Hormone Drug Sales Market Share by Country (2020-2031)
Figure 33. North America Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Country (2020-2031)
Figure 34. United States Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Canada Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Europe Growth Hormone Inhibiting Hormone Drug Sales Market Share by Country (2020-2031)
Figure 37. Europe Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Country (2020-2031)
Figure 38. Germany Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. France Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. U.K. Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Italy Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Russia Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Asia Pacific Growth Hormone Inhibiting Hormone Drug Sales Market Share by Region (2020-2031)
Figure 44. Asia Pacific Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Region (2020-2031)
Figure 45. China Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Japan Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. South Korea Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. India Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Australia Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. China Taiwan Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Southeast Asia Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Latin America Growth Hormone Inhibiting Hormone Drug Sales Market Share by Country (2020-2031)
Figure 53. Latin America Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Country (2020-2031)
Figure 54. Mexico Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Brazil Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Argentina Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Colombia Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Sales Market Share by Country (2020-2031)
Figure 59. Middle East and Africa Growth Hormone Inhibiting Hormone Drug Revenue Market Share by Country (2020-2031)
Figure 60. Turkey Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 61. Saudi Arabia Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 62. UAE Growth Hormone Inhibiting Hormone Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 63. Global Sales Market Share of Growth Hormone Inhibiting Hormone Drug by Type (2020-2031)
Figure 64. Global Revenue Market Share of Growth Hormone Inhibiting Hormone Drug by Type (2020-2031)
Figure 65. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Type (2020-2031)
Figure 66. Global Sales Market Share of Growth Hormone Inhibiting Hormone Drug by Application (2020-2031)
Figure 67. Global Revenue Market Share of Growth Hormone Inhibiting Hormone Drug by Application (2020-2031)
Figure 68. Global Growth Hormone Inhibiting Hormone Drug Price (US$/Unit) by Application (2020-2031)
Figure 69. Growth Hormone Inhibiting Hormone Drug Value Chain
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
